References
[1] Calvert PA, Rana BS, Kydd AC, et al. Patent foramen ovale: anatomy, outcomes, and closure. Nat Rev Cardiol. 2011, 8(3):148-60.
[2] Mojadidi MK, Zaman MO, Elgendy IY, et al. Cryptogenic Stroke and Patent Foramen Ovale. J Am Coll Cardiol. 2018; 71 (9):1035-1043.
[3] Mohammad Abdelghani , Sahar A O El-Shedoudy , Martina Nassif , et al. Management of Patients with Patent Foramen Ovale and Cryptogenic Stroke: An Update. Cardiology.  2019; 143(1):62-72.
[4] Vaidya K, Khandkar C, Celermajer D.Current management aspects in adult congenital heart disease: non-surgical closure of patent foramen ovale. Cardiovasc Diagn Ther. 2018; 8(6):739-753.
[5] Xu WZ, Shou XY, Li JH, et al. Non-fluoroscopic percutaneous transcatheter closure of atrial septal defects in children under transesophageal echocardiographic guidance. World J Pediatr.  2018; 14(4):378-382.
[6] Pan XB, Ou-Yang WB, Pang KJ, et al. Percutaneous closure of atrial septal defects under transthoracic echocardiography guidance without fluoroscopy or intubation in children. J Interv Cardiol. 2015; 28(4):390–5.
[7] Lattanzi S, Brigo F, Cagnetti C, et al. Patent Foramen Ovale and Cryptogenic Stroke or Transient Ischemic Attack: To Close or Not to Close? A Systematic Review and Meta-Analysis. Cerebrovasc Dis. 2018; 45(5-6):193-203.
[8] Bedeir K, Volpi J, Ramlawi B. Cryptogenic Stroke with a Patent Foramen Ovale: Medical Therapy, Percutaneous Intervention, or Surgery. J Card Surg. 2016; 31(3):156-60.
[9] Diener HC, Gerloff C, Thaler DE, et al. Closure of patent foramen ovale and cryptogenic stroke: unresolved issues. Curr Neurol Neurosci Rep. 2018;18(12):92.
[10] Takagi H, Umemoto T. A meta-analysis of case-control studies of the association of migraine and patent foramen ovale. J Cardiol. 2016 ; 67(6): 493-503.
[11] Tobis JM, Charles A, Silberstein SD, et al. Percutaneous Closure of Patent Foramen Ovale in Patients With Migraine: The PREMIUM Trial. J Am Coll Cardiol. 2017; 70(22): 2766-2774.
[12] Mas JL, Derumeaux G, Guillon B, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med. 2017; 377(11):1011-1021.
[13] Søndergaard L, Krasner SE, Rhodes JF, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med. 2017Sep, 377(11), 1033–1042.
[14] Kasner SE, Swaminathan B, Lavados P, Sharma M, Muir K, Veltkamp R,et al. Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial. Lancet Neurol .2018; 17(12):1053-1060.
[15] Stortecky S, da Costa BR, Mattle HP, et al. Percutaneous closure of patent foramen ovale in patients with cryptogenic embolism: a network meta-analysis. Eur Heart J. 2015; 36(2): 120-128.